Evidence map›Paper›PMID 38261726›Full record

ArticleCardiovascular research2024

The Kir2.1E299V mutation increases atrial fibrillation vulnerability while protecting the ventricles against arrhythmias in a mouse model of short QT syndrome type 3.

Ana I Moreno-Manuel, Álvaro Macías, Francisco M Cruz, Lilian K Gutiérrez, Fernando Martínez, Andrés González-Guerra, Isabel Martínez Carrascoso, Francisco José Bermúdez-Jimenez, Patricia Sánchez-Pérez, María Linarejos Vera-Pedrosa and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Cardiovascular research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 13 citations in OpenAlex.

  1. NovelBiomedicines · 2026
    Article
  2. Article
  3. Rare TruncatingGenes · 2026
    Article
  4. Article
  5. Supraventricular tachycardias in ion channel diseases.Herzschrittmachertherapie & Elektrophysiologie · 2026
    Review
  6. Discovery ofDiagnostics (Basel, Switzerland) · 2025
    Article
  7. MOG1medRxiv : the preprint server for health sciences · 2025
    Article
  8. Review
  9. Animal and cellular models of atrial fibrillation: a review.Frontiers in cardiovascular medicine · 2025
    Review
  10. Article
  11. Article
  12. Identification and Functional Investigation ofDiagnostics (Basel, Switzerland) · 2024
    Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Ana I Moreno-ManuelCentro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernández Almagro 3, 28029 Madrid, Spain.ORCID 0000-0002-5011-2786
Álvaro MacíasCentro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernández Almagro 3, 28029 Madrid, Spain.ORCID 0000-0002-9952-6947
Francisco M CruzCentro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernández Almagro 3, 28029 Madrid, Spain.ORCID 0000-0001-5330-8613
Lilian K GutiérrezCentro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernández Almagro 3, 28029 Madrid, Spain.
Fernando MartínezCentro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernández Almagro 3, 28029 Madrid, Spain.
Andrés González-GuerraCentro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernández Almagro 3, 28029 Madrid, Spain.
Isabel Martínez CarrascosoCentro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernández Almagro 3, 28029 Madrid, Spain.
Francisco José Bermúdez-JimenezCentro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernández Almagro 3, 28029 Madrid, Spain.
Patricia Sánchez-PérezCentro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernández Almagro 3, 28029 Madrid, Spain.
María Linarejos Vera-PedrosaCentro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernández Almagro 3, 28029 Madrid, Spain.
Juan Manuel Ruiz-RoblesCentro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernández Almagro 3, 28029 Madrid, Spain.
Juan A BernalCentro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernández Almagro 3, 28029 Madrid, Spain.ORCID 0000-0002-9933-5550
José JalifeCentro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernández Almagro 3, 28029 Madrid, Spain.ORCID 0000-0003-0080-3500
Spanish National Centre for Cardiovascular Research · ESUniversity of Michigan · US

Funding

Dynamic Microscopy and Imaging Unit-ICTS-ReDib ICTS-2018-04-CNIC-16European Union's Horizon 2020 Research and Innovation Programme GA-965286Fondo Europeo de Desarrollo RegionalFundación La Marató de TV3 736/C/2020Instituto de Salud Carlos III BFU2016-75144-RLa Caixa Banking Foundation LCF/PR/HR19/52160013Ministerio de Ciencia e InnovaciónPro CNIC FoundationSevero Ochoa Center of Excellence CEX2020-001041-S
6 · The paper itself

Abstract

aimsShort QT syndrome type 3 (SQTS3) is a rare arrhythmogenic disease caused by gain-of-function mutations in KCNJ2, the gene coding the inward rectifier potassium channel Kir2.1. We used a multidisciplinary approach and investigated arrhythmogenic mechanisms in an in-vivo model of de-novo mutation Kir2.1E299V identified in a patient presenting an extremely abbreviated QT interval and paroxysmal atrial fibrillation. METHODS AND

resultsWe used intravenous adeno-associated virus-mediated gene transfer to generate mouse models, and confirmed cardiac-specific expression of Kir2.1WT or Kir2.1E299V. On ECG, the Kir2.1E299V mouse recapitulated the QT interval shortening and the atrial-specific arrhythmia of the patient. The PR interval was also significantly shorter in Kir2.1E299V mice. Patch-clamping showed extremely abbreviated action potentials in both atrial and ventricular Kir2.1E299V cardiomyocytes due to a lack of inward-going rectification and increased IK1 at voltages positive to -80 mV. Relative to Kir2.1WT, atrial Kir2.1E299V cardiomyocytes had a significantly reduced slope conductance at voltages negative to -80 mV. After confirming a higher proportion of heterotetrameric Kir2.x channels containing Kir2.2 subunits in the atria, in-silico 3D simulations predicted an atrial-specific impairment of polyamine block and reduced pore diameter in the Kir2.1E299V-Kir2.2WT channel. In ventricular cardiomyocytes, the mutation increased excitability by shifting INa activation and inactivation in the hyperpolarizing direction, which protected the ventricle against arrhythmia. Moreover, Purkinje myocytes from Kir2.1E299V mice manifested substantially higher INa density than Kir2.1WT, explaining the abbreviation in the PR interval.

conclusionThe first in-vivo mouse model of cardiac-specific SQTS3 recapitulates the electrophysiological phenotype of a patient with the Kir2.1E299V mutation. Kir2.1E299V eliminates rectification in both cardiac chambers but protects against ventricular arrhythmias by increasing excitability in both Purkinje-fiber network and ventricles. Consequently, the predominant arrhythmias are supraventricular likely due to the lack of inward rectification and atrial-specific reduced pore diameter of the Kir2.1E299V-Kir2.2WT heterotetramer.

Indexed as

Atrial FibrillationDisease Models, AnimalMyocytes, CardiacPotassium Channels, Inwardly RectifyingAction PotentialsAnimalsArrhythmias, CardiacGenetic Predisposition to DiseaseHeart RateHeart VentriclesHumansMiceMice, Inbred C57BLMice, TransgenicMutationPhenotypeKCNJ2 protein, humanKir2.1 channelPotassium Channels, Inwardly RectifyingAction potential durationAtrial and ventricular arrhythmiasElectrocardiogramExcitabilityKir2.1-Nav1.5 channelosome

Identifiers

PMID38261726
PMCPMC11060485
OpenAlexW4391131283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.